(Q43041036)

12 November 2017

title

Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

1

1 reference

12 November 2017

8

1 reference

12 November 2017

10

1 reference

12 November 2017

11

1 reference

12 November 2017

J A Mira

2

1 reference

12 November 2017

I Gilabert

3

1 reference

12 November 2017

E Claro

4

1 reference

12 November 2017

M J Vázquez

5

1 reference

12 November 2017

C Cifuentes

6

1 reference

12 November 2017

S García-Rey

7

1 reference

12 November 2017

C Almeida

9

1 reference

12 November 2017

publication date

6 October 2011

1 reference

European Journal of Clinical Microbiology & Infectious Diseases

12 November 2017

published in

1 reference

12 November 2017

volume

31

1 reference

12 November 2017

issue

6

1 reference

12 November 2017

page(s)

1225-1232

1 reference

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Global estimates of prevalence of HCV infection among injecting drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Hepatitis C treatment for injection drug users: a review of the available evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Limited uptake of hepatitis C treatment among injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Is the management of hepatitis C patients appropriate? A population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Feasibility and Outcome of HCV Treatment in a Canadian Federal Prison Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Treating hepatitis C virus infection in active substance users

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Peginterferon plus Ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1433-5

Treatment of hepatitis C viral infections in substance abusers.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21971821

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prevention of spread of hepatitis C.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21971821

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10096-011-1433-5

1 reference

Dimensions Publication ID

12 November 2017

1030256554

0 references

1 reference